Ethacrynic acid (tablet): Difference between revisions

Ethacrynic acid (tablet)
	Black Box Warning
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

VisualWikitext

Revision as of 03:00, 1 July 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title

See full prescribing information for complete Boxed Warning.

ConditionName: Content

Overview

Ethacrynic acid (tablet) is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1

Dosing Information

Dosage

Condition2

Dosing Information

Dosage

Condition3

Dosing Information

Dosage

Condition4

Dosing Information

Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Ethacrynic acid (tablet) in adult patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ethacrynic acid (tablet) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Ethacrynic acid (tablet) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Ethacrynic acid (tablet) in pediatric patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ethacrynic acid (tablet) in pediatric patients.

Contraindications

Condition1

Warnings

Title

See full prescribing information for complete Boxed Warning.

ConditionName: Content

Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Ethacrynic acid (tablet) in the drug label.

Central Nervous System

Cardiovascular

Respiratory

Gastrointestinal

Hypersensitivity

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Ethacrynic acid (tablet) in the drug label.

Central Nervous System

Cardiovascular

Respiratory

Gastrointestinal

Hypersensitivity

Miscellaneous

Drug Interactions

Drug

Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ethacrynic acid (tablet) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ethacrynic acid (tablet) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ethacrynic acid (tablet) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ethacrynic acid (tablet) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ethacrynic acid (tablet) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ethacrynic acid (tablet) in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Ethacrynic acid (tablet) in the drug label.

Condition1

Description

IV Compatibility

There is limited information regarding IV Compatibility of Ethacrynic acid (tablet) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Ethacrynic acid (tablet) in the drug label.

Pharmacology

There is limited information regarding Ethacrynic acid (tablet) Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Ethacrynic acid (tablet) Mechanism of Action in the drug label.

Structure

There is limited information regarding Structure of Ethacrynic acid (tablet) in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Ethacrynic acid (tablet) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Ethacrynic acid (tablet) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Ethacrynic acid (tablet) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Ethacrynic acid (tablet) in the drug label.

Condition1

Description

How Supplied

There is limited information regarding Ethacrynic acid (tablet) How Supplied in the drug label.

Storage

There is limited information regarding Ethacrynic acid (tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Ethacrynic acid (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ethacrynic acid (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Ethacrynic acid (tablet) in the drug label.

Precautions with Alcohol

Alcohol-Ethacrynic acid (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Ethacrynic acid (tablet) Brand Names in the drug label.

Look-Alike Drug Names

A® — B®^[1]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Ethacrynic acid (tablet)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Ethacrynic acid (tablet)
 |Label Name=No image.jpg

}}

[www.ismp.org-1] "http://www.ismp.org". External link in |title= (help)

[1]

@@ Line 1: / Line 1: @@
-{{drugbox
+{{DrugProjectFormSinglePage
-| IUPAC_name = 2-[2,3-dichloro-4-(2-methylidenebutanoyl) phenoxy] acetic acid
+|authorTag=
-| image = Ethacrynic acid.svg
-| CAS_number = 58-54-8
-| ATC_prefix =
+<!--Overview-->
-| ATC_suffix =
-| ATC_supplemental =
+|genericName=
-| PubChem = 3278
-| DrugBank = APRD00251
-| C=13 | H=12 | Cl=2 | O=4
+|aOrAn=
-| molecular_weight = 303.137 g/mol
+a
-| bioavailability =
-| protein_bound = > 98%
+|drugClass=
-| metabolism =
-| elimination_half-life =
-| pregnancy_category =
+|indication=
-| legal_status =
-| routes_of_administration =
-}}
+|hasBlackBoxWarning=
-'''Ethacrynic acid''' (trade name '''Edecrin''') is a [[loop diuretic]] [[medication]] used to treat [[hypertension|high blood pressure]] and the [[edema|swelling]] caused by diseases like [[congestive heart failure]], [[liver failure]], and [[kidney failure]]. Unlike the other loop diuretics, ethacrynic acid is not a [[Sulfonamide (medicine)|sulfonamide]] and thus, its use is not contraindicated in those with sulfur allergies.
+Yes
-Ethacrynic acid is a phenoxyacetic acid derivative containing a ketone and a methylene group. A cysteine adduct is formed with the methylene group and this is the active form.
+|adverseReactions=
+<!--Black Box Warning-->
+|blackBoxWarningTitle=
+Title
+|blackBoxWarningBody=
+<i><span style="color:#FF0000;">ConditionName: </span></i>Content
+<!--Adult Indications and Dosage-->
+<!--FDA-Labeled Indications and Dosage (Adult)-->
+|fdaLIADAdult=
+=====Condition1=====
+* Dosing Information
+:* Dosage
+=====Condition2=====
+* Dosing Information
+:* Dosage
+=====Condition3=====
+* Dosing Information
+:* Dosage
+=====Condition4=====
+* Dosing Information
+:* Dosage
+<!--Off-Label Use and Dosage (Adult)-->
+<!--Guideline-Supported Use (Adult)-->
+|offLabelAdultGuideSupport=
+=====Condition1=====
+* Developed by:
+* Class of Recommendation:
+* Strength of Evidence:
+* Dosing Information
+:* Dosage
+=====Condition2=====
+There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
+<!--Non–Guideline-Supported Use (Adult)-->
+|offLabelAdultNoGuideSupport=
+=====Condition1=====
+* Dosing Information
+:* Dosage
+=====Condition2=====
+There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
+<!--Pediatric Indications and Dosage-->
+<!--FDA-Labeled Indications and Dosage (Pediatric)-->
+|fdaLIADPed=
+=====Condition1=====
+* Dosing Information
+:* Dosage
+=====Condition2=====
+There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
+<!--Off-Label Use and Dosage (Pediatric)-->
+<!--Guideline-Supported Use (Pediatric)-->
+|offLabelPedGuideSupport=
+=====Condition1=====
+* Developed by:
+* Class of Recommendation:
+* Strength of Evidence:
+* Dosing Information
+:* Dosage
+=====Condition2=====
+There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
+<!--Non–Guideline-Supported Use (Pediatric)-->
+|offLabelPedNoGuideSupport=
+=====Condition1=====
+* Dosing Information
+:* Dosage
+=====Condition2=====
+There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
+<!--Contraindications-->
+|contraindications=
+* Condition1
+<!--Warnings-->
+|warnings=
+Description
+<!--Adverse Reactions-->
+<!--Clinical Trials Experience-->
+|clinicalTrials=
+There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
+======Central Nervous System======
+======Cardiovascular======
+======Respiratory======
+======Gastrointestinal======
+======Hypersensitivity======
+======Miscellaneous======
+<!--Postmarketing Experience-->
+|postmarketing=
+There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
+======Central Nervous System======
+======Cardiovascular======
+======Respiratory======
+======Gastrointestinal======
+======Hypersensitivity======
+======Miscellaneous======
+<!--Drug Interactions-->
+|drugInteractions=
+* Drug
+:* Description
+<!--Use in Specific Populations-->
+|useInPregnancyFDA=
+* '''Pregnancy Category'''
+|useInPregnancyAUS=
+* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
+There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
+|useInLaborDelivery=
+There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
+|useInNursing=
+There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
+|useInPed=
+There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
+|useInGeri=
+There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
+|useInGender=
+There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
+|useInRace=
+There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
+|useInRenalImpair=
+There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
+|useInHepaticImpair=
+There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
+|useInReproPotential=
+There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
+|useInImmunocomp=
+There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
+<!--Administration and Monitoring-->
+|administration=
+Oral
+Intravenous
+|monitoring=
+There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
+=====Condition1=====
+Description
+<!--IV Compatibility-->
+|IVCompat=
+There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
+<!--Overdosage-->
+|overdose=
+===Acute Overdose===
+====Signs and Symptoms====
+Description
+====Management====
+Description
+===Chronic Overdose===
+There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
+<!--Pharmacology-->
+<!--Drugbox2-->
+|drugBox=
+<!--Mechanism of Action-->
+|mechAction=
+<!--Structure-->
+|structure=
+There is limited information regarding <i>Structure</i> of {{PAGENAME}} in the drug label.
+<!--Pharmacodynamics-->
+|PD=
+There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
+<!--Pharmacokinetics-->
+|PK=
+There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
+<!--Nonclinical Toxicology-->
+|nonClinToxic=
+There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
+<!--Clinical Studies-->
+|clinicalStudies=
+There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
+=====Condition1=====
+Description
+<!--How Supplied-->
+|howSupplied=
+<!--Patient Counseling Information-->
+|fdaPatientInfo=
+There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
+<!--Precautions with Alcohol-->
+|alcohol=
+Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
+<!--Brand Names-->
+|brandNames=
+<!--Look-Alike Drug Names-->
+|lookAlike=
+* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
-==Administration==
+<!--Drug Shortage Status-->
-mg and 50 mg tablets are available for oral use. The sodium salt (ethacrynate sodium) can also be given [[intravenous therapy|intravenous]]ly.
-==Side effects==
+|drugShortage=
-As a [[diuretic]], ethacrynic acid can cause frequent urination, but this usually resolves after taking the drug for a few weeks.
+}}
-Ethacrynic acid can also cause [[hypokalemia|low potassium levels]], which may manifest as muscle cramps or weakness. It has also been known to cause reversible or permanent hearing loss and liver damage. On oral administration, it produces diarrhea; intestinal bleeding may occur at higher doses.
+<!--Pill Image-->
-[[Category:Loop diuretics]]
+{{PillImage
+|fileName=No image.jpg|This image is provided by the National Library of Medicine.
+|drugName=
+|NDC=
+|drugAuthor=
+|ingredients=
+|pillImprint=
+|dosageValue=
+|dosageUnit=
+|pillColor=
+|pillShape=
+|pillSize=
+|pillScore=
+}}
+<!--Label Display Image-->
-{{pharma-stub}}
+{{LabelImage
+|fileName=No image.jpg|This image is provided by the National Library of Medicine.
+}}
-[[de:Etacrynsäure]]
+<!--Category-->
-[[pl:Kwas etakrynowy]]
-MECHANISM OF ACTION
+[[Category:Cardiovascular Drugs]]
-Acts by inhibiting sodim-potassium-chloride cotransport in the  ascending loop of Henle. Loss of potassium ions is less marked but chances of hypochloremic alkalosis are greater. The dose response curve of ethacrynic acid is steeper than that of furosemide and, in general, it is less manageable; dose range is 50-150mg.
+[[Category:Drug]]